GLP-1 Receptor Agonists and Increased Risk of Tendon Injury in Athletes

Why It Matters

The findings flag a hidden safety concern for the growing cohort of endurance athletes using GLP‑1 drugs, potentially affecting performance, medical costs, and prescribing practices in sports medicine.

Key Takeaways

• GLP‑1 drugs raise tendon injury risk 50% in athletes.
• Achilles rupture risk climbs to 0.3% versus 0.2% baseline.
• Muscle loss up to 38% of weight loss strains tendons.
• Strength training and protein can cut lean‑mass loss 50‑90%.
• 7% of obese U.S. adults prescribed GLP‑1s by 2024.

Pulse Analysis

The surge in GLP‑1 receptor agonist prescriptions has reshaped obesity treatment, delivering average weight reductions of 14‑20% and attracting athletes seeking leaner physiques. By 2024, roughly seven percent of obese Americans were on these drugs, and the market’s aggressive marketing has extended their reach into endurance sports where caloric efficiency is paramount. This rapid adoption, however, has outpaced long‑term safety data, prompting researchers to scrutinize side effects beyond the well‑known gastrointestinal profile.

At the recent American Academy of Orthopedic Surgeons meeting, investigators reported a statistically significant 50% uptick in tendon injuries among GLP‑1 users compared with non‑users. While absolute rupture rates remain modest—Achilles injuries rose from 0.2% to 0.3% and rotator‑cuff tears from 1.5% to 2.4%—the relative increase is noteworthy for athletes whose training hinges on musculoskeletal integrity. The hypothesized mechanism centers on the drugs’ appetite‑suppressing effect, which often leads to substantial caloric deficits and concomitant loss of lean muscle mass, accounting for up to 38% of total weight loss. Reduced muscle buffering can place disproportionate stress on tendons, heightening rupture risk during high‑volume endurance training.

For athletes, the emerging evidence calls for a proactive approach. Integrating 60‑90 minutes of strength work weekly and ensuring sufficient protein intake can preserve up to 90% of lean mass, mitigating tendon strain. Sports physicians and coaches must weigh the performance benefits of rapid fat loss against the potential for injury, especially in disciplines like triathlon where sustained power output and joint health are critical. As GLP‑1 utilization continues to expand, further longitudinal studies will be essential to refine guidelines and safeguard athlete health.